Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

American Journal of Cardiology

Volumn 93, Issue 7, 2004, Pages 943-946

  Ivy, D Dunbar ^a,b   Doran, Aimee ^a   Claussen, Lori ^a   Bingaman, Deborah ^a   Yetman, Anji ^a  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PROSTACYCLIN;

ADOLESCENT; ARTICLE; BONE PAIN; CLINICAL ARTICLE; DIARRHEA; DRUG ERUPTION; DRUG MEGADOSE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEMODYNAMIC PARAMETERS; HUMAN; JAW; LUNG ARTERY PRESSURE; MALE; NAUSEA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN; VOMITING; WEANING;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; SULFONAMIDES; VASCULAR RESISTANCE;

EID: 1842476943     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.12.031     Document Type: Article

References (11)

1. Rubin L.J., Mendoza J., Hood M., McGoon M., Barst R., Williams W.B., Diehl J.H., Crow J., Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 112:1990;485-491.
2. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., Groves B.M., Tapson V.F., Bourge R.C., Brundage B.H., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 334:1996;296-302.
3. McLaughlin V.V., Genthner D.E., Panella M.M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 338:1998;273-277.
4. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 99:1999;1197-1208.
5. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., Rainisio M., Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension prognostic factors and survival. J Am Coll Cardiol. 40:2002;780-788.
6. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension the impact of epoprostenol therapy. Circulation. 106:2002;1477-1482.
7. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739.
8. Rubens C., Ewert R., Halank M., Wensel R., Orzechowski H.D., Schultheiss H.P., Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 120:2001;1562-1569.
9. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903.
10. Barst R.J., Ivy D., Dingemanse J., Widlitz A., Schmitt K., Doran A., Bingaman D., Nguyen N., Gaitonde M., van Giersbergen P.L. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 73:2003;372-382.
11. Kim N.H., Channick R.N., Rubin L.J. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 124:2003;1612-1615.